Purchase this article with an account.
E.G. Romanowski, R.P. Kowalski, K.A. Yates, F.S. Mah, Y.J. Gordon; Vigamox® (0.5% Moxifloxacin) Is Effective in Reducing Staphylococcus aureus Colony Counts in a NZW Rabbit Endophthalmitis Model . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1899.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The goal of the current study was to determine whether the commercially available and self–preserved Vigamox® (0.5% moxifloxacin ophthalmic solution, Alcon Laboratories, Ft. Worth, TX) could be used as an effective treatment of an established endophthalmitis in the NZW rabbit endophthalmitis model.
The left eyes of 24 NZW rabbits were inoculated into the vitreous with approximately 500 cfu of a clinical endophthalmitis isolate of Staphylococcus aureus. 24 hours post–inoculation, the rabbits were randomly divided into 3 groups of 8 rabbits each. Group I eyes were treated intravitreally with 100 µl of Vigamox® (500 µg of moxifloxacin). Group II eyes were treated intravitreally with 100 µl of 10 mg/ml vancomycin (1 mg of vancomycin). Group III eyes received no treatment (Control). 24 hours post–treatment and 48 hours post–inoculation, the rabbits were euthanized and samples of vitreous were removed from the test eyes for standard colony count evaluation. Colony counts were Log10 transformed and analyzed using ANOVA.
Both the Vigamox® (1.6 ± 1.6 Log10 cfu/ml) and vancomycin (0.1 ± 0.3 Log10 cfu/ml) treated eyes demonstrated significantly fewer S. aureus colony counts compared to the untreated Control (4.7 ± 2.0 Log10 cfu/ml) (p=0.000, power = 0.9996). There was no significant difference in colony counts between the Vigamox® and vancomycin treated eyes.
Intravitreal Vigamox® was as effective as vancomycin in the NZW rabbit endophthalmitis model using microbiological outcome parameters. Based on the results of this study, Vigamox® may have the potential be an effective adjunctive treatment for S. aureus endophthalmitis. However, clinical trials are necessary to determine the safety and efficacy of Vigamox® treatment of endophthalmitis in patients.
This PDF is available to Subscribers Only